- Acute rhinitis, a condition characterized by nasal inflammation due to viral infections or allergens, is witnessing rising prevalence globally, particularly with increasing exposure to environmental irritants and fluctuating weather conditions. The condition is commonly managed through over-the-counter medications, antihistamines, and nasal decongestants, making it a significant contributor to the global respiratory therapeutics market
- The rising incidence of upper respiratory tract infections, increasing air pollution, and heightened public health awareness are the primary drivers fueling demand in the acute rhinitis treatment market. Additionally, advancements in intranasal drug delivery technologies and the growing availability of combination therapies are accelerating market growth
- North America dominated the acute rhinitis market, capturing the largest revenue share of 41.3% in 2024, driven by a well-established healthcare infrastructure, high patient awareness levels, and the widespread availability of effective OTC and prescription treatments
- Asia-Pacific region is projected to be the fastest-growing market for acute rhinitis during the forecast period (2025–2032), with a CAGR of 8.7%, fueled by rapid urbanization, rising pollution levels, increased healthcare spending, and a surge in allergic rhinitis cases in countries like China and India
- The allergic segment dominated the acute rhinitis market in 2024, accounting for 61.4% of global revenue, driven by the increasing prevalence of seasonal allergic rhinitis, heightened exposure to environmental allergens such as pollen and dust, and rising public awareness about allergy management
